GE Healthcare Invests in FISH Technologies for Leukemia and Lymphoma Testing

GE Healthcare Technologies invests in fish for leukemia and lymphoma test
GE Healthcare today announced that Clarient Diagnostic Services, Inc., a business of GE Healthcare has made significant improvements to its fluorescence in situ hybridization technology to improve virtual analysis of the test results for a variety of diseases blood, including leukemia, lymphoma, myeloma and myelodysplastic syndrome.

Both comments and pings are currently closed.

Comments are closed.